{"product_id":"vktx-ansoff-analysis","title":"(VKTX) Viking Therapeutics, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Ansoff Matrix Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Viking Therapeutics, Inc. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification, showing how pipeline programs and target markets align with each quadrant; the page includes a real preview\/sample so you can judge style and depth before buying. Purchase the full version to receive the complete, ready-to-use analysis for strategy, investing, or presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVK2809 Phase IIb NASH concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVK2809 is Viking Therapeutics’ lead oral thyroid hormone receptor beta agonist, in Phase IIb for biopsy-confirmed NASH and NAFLD. The VOYAGE study enrolled about 340 patients, keeping Viking concentrated on its most advanced liver asset. That focus helps deepen share in a market where NASH affects roughly 5% to 7% of U.S. adults.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVK2809 NAFLD development depth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVK2809 extends Viking Therapeutics, Inc. deeper into NAFLD, a market that affects about 1 in 4 adults worldwide, so the same lead asset can build a second liver-disease use case without leaving the metabolic franchise. That tighter focus can strengthen clinical visibility in one disease cluster and sharpen market penetration versus a broad pipeline spread.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVK5211 hip-fracture recovery focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVK5211 is Viking Therapeutics, Inc.’s oral, non-steroidal selective androgen receptor modulator in Phase II for recovery after non-elective hip fracture surgery. The focus on one defined musculoskeletal use case supports market penetration by deepening access in a high-need segment, where about 1.6 million hip fractures occur worldwide each year. If the program improves post-op recovery, it could strengthen Viking Therapeutics, Inc.’s position in a market with clear unmet need.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVK0612 type 2 diabetes focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVK0612 fits Viking Therapeutics, Inc.'s metabolic pipeline and targets type 2 diabetes, a huge current market with about 38.4 million U.S. adults affected in 2024. As an oral candidate, it could deepen Viking Therapeutics, Inc.'s reach in a core disease area already aligned with its endocrine focus. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOral dose may support adoption.\u003c\/li\u003e\n\u003cli\u003eBuilds on existing metabolic R\u0026amp;D.\u003c\/li\u003e\n\u003cli\u003eTargets a large, proven demand pool.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eManagement said Viking Therapeutics, Inc. ended 2024 with $903.6 million in cash, giving it room to keep VK0612 moving without near-term financing pressure. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVK0214 X-linked adrenoleukodystrophy focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVK0214 extends Viking Therapeutics, Inc.’s rare-disease push in X-linked adrenoleukodystrophy, a disorder that affects about 1 in 17,000 people worldwide. As an oral, tissue- and receptor-selective TRß agonist, it keeps the Company in a niche with high unmet need and low direct competition. Active development can deepen its foothold before any launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare disease: about 1 in 17,000.\u003c\/li\u003e\n\u003cli\u003eOral dosing may aid adoption.\u003c\/li\u003e\n\u003cli\u003eTRß selectivity supports targeting.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eViking’s Cash-Backed Push Across Metabolic Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eViking Therapeutics, Inc. uses market penetration by pushing one metabolic-liver core across bigger, familiar patient pools: VK2809 in NASH\/NAFLD, VK0612 in type 2 diabetes, and VK5211 in post-hip-fracture recovery. The Company ended 2024 with $903.6 million in cash, so it can keep these programs moving without near-term funding strain.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVK2809\u003c\/td\u003e\n\u003ctd\u003eNASH\/NAFLD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVK0612\u003c\/td\u003e\n\u003ctd\u003eType 2 diabetes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVK5211\u003c\/td\u003e\n\u003ctd\u003eHip fracture recovery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing Viking Therapeutics, Inc.’s growth strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Viking Therapeutics Ansoff snapshot to simplify growth strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, credible Viking Therapeutics sources to validate Ansoff Matrix growth assumptions and speed due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVK2809 from NASH to NAFLD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVK2809 is already being tested in biopsy-confirmed NASH, so the NAFLD program is an existing-product move into a wider fatty-liver market. That fits Ansoff's market development: same asset, broader patient pool.\u003c\/p\u003e\n\u003cp\u003eThe move matters because NAFLD is far larger than biopsy-confirmed NASH, and even a modest share can scale revenue faster than a narrow fibrosis-only use case.\u003c\/p\u003e\n\u003cp\u003eViking Therapeutics, Inc. is using one mechanism, the THR-β agonist VK2809, to stretch clinical reach without changing the core drug.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVK5211 into post-surgical recovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVK5211 moves Viking Therapeutics, Inc. into post-surgical recovery by targeting non-elective hip fracture surgery, a care setting with about 300,000 U.S. hospitalizations a year. It shifts one existing asset from liver and endocrine work into a new, acute recovery market. That broadens Viking Therapeutics, Inc.'s reach beyond its core pipeline and into hospital-based care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVK0612 into type 2 diabetes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVK0612 expands Viking Therapeutics, Inc. beyond liver disease into type 2 diabetes, a much larger endocrine market. The International Diabetes Federation said 589 million adults were living with diabetes in 2024, and 90% to 95% of cases are type 2, so the addressable pool is huge. That broadens Viking Therapeutics, Inc.'s pipeline and reduces reliance on its liver assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVK0214 into X-linked adrenoleukodystrophy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVK0214’s move into X-linked adrenoleukodystrophy shifts Viking Therapeutics, Inc. from metabolic disease into a rare-disease niche, widening the oral TRß agonist platform. X-ALD affects about 1 in 14,700 male births, so this is a small but high-need market with limited treatment depth. The move adds a new therapeutic segment and supports portfolio expansion with one asset.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew rare-disease segment\u003c\/li\u003e\n\u003cli\u003eOral TRß agonist repositioning\u003c\/li\u003e\n\u003cli\u003eX-ALD: ~1 in 14,700 male births\u003c\/li\u003e\n\u003cli\u003ePipeline breadth increases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMultiple therapeutic areas from one pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eViking Therapeutics is turning one pipeline into multiple shots on goal: VK2735, VK2809, and VK0214 span metabolic, endocrine, musculoskeletal, and rare-disease use cases. That is market development through indication expansion, not a new product launch. As of Q1 2025, Viking had about $903.6 million in cash and investments, giving it room to fund several programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne asset, more patient groups.\u003c\/li\u003e\n\u003cli\u003eSpans 4 therapeutic areas.\u003c\/li\u003e\n\u003cli\u003eUses existing R\u0026amp;D across indications.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eViking Expands Its Pipeline Into Bigger Patient Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eViking Therapeutics, Inc. uses existing assets to enter bigger or new patient groups, which is classic market development. VK2809 widens liver use beyond biopsy-confirmed NASH, VK0612 enters type 2 diabetes, and VK5211 targets post-hip-fracture recovery. This expands reach without changing the core platform.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVK2809\u003c\/td\u003e\n\u003ctd\u003eNAFLD\u003c\/td\u003e\n\u003ctd\u003eBroader than NASH\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVK0612\u003c\/td\u003e\n\u003ctd\u003eType 2 diabetes\u003c\/td\u003e\n\u003ctd\u003e589M adults had diabetes in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVK5211\u003c\/td\u003e\n\u003ctd\u003eHip fracture recovery\u003c\/td\u003e\n\u003ctd\u003e~300,000 U.S. hospitalizations\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eViking Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVK2809 oral TRß agonist\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVK2809 is Viking Therapeutics, Inc.'s oral, tissue- and receptor-selective TRß agonist, a new product for the liver-disease market. In 2025, biopsy-confirmed NASH affects about 5% of U.S. adults and NAFLD about 30% of adults worldwide, so the target pool is large. \u003c\/p\u003e\n\u003cp\u003eFor Ansoff, this is product development: a new therapy for an existing therapeutic area. \u003c\/p\u003e\n\u003cp\u003eIts Phase 2 data showed up to 62% relative liver-fat reduction at 12 weeks in some doses, supporting its market-entry case. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVK5211 non-steroidal SARM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVK5211 is Viking Therapeutics, Inc.'s oral, non-steroidal SARM for recovery after non-elective hip fracture surgery, targeting a new musculoskeletal use case. Hip fractures drive about 300,000 U.S. hospitalizations a year, so even modest recovery gains could matter clinically and commercially. In Ansoff terms, this is product development: a new drug for an existing care area, with clear unmet need and high value per patient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVK0612 oral diabetes candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVK0612 is Viking Therapeutics, Inc.'s oral candidate for type 2 diabetes, adding a new product to the diabetes market. Type 2 diabetes affects about 589 million adults worldwide, so even one oral option can matter. The program also widens Viking Therapeutics, Inc.'s metabolic disease lineup beyond its existing pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVK0214 rare-disease TRß agonist\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVK0214 is Viking Therapeutics, Inc.’s orally active, tissue- and receptor-selective TRß agonist for X-linked adrenoleukodystrophy, a rare disease that affects about 1 in 20,000 male births. As a new product for an orphan indication, it expands Viking Therapeutics, Inc. beyond cardiometabolic programs and targets a high-unmet-need niche with limited approved options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOral TRß agonist\u003c\/li\u003e\n\u003cli\u003eRare-disease expansion\u003c\/li\u003e\n\u003cli\u003eX-linked adrenoleukodystrophy\u003c\/li\u003e\n\u003cli\u003eHigh unmet need\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOral small-molecule pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eViking Therapeutics, Inc. is using oral small molecules as the main engine of product development: VK2809 for MASH, VK0214 for X-linked adrenoleukodystrophy, and oral VK2735 for obesity. That matters because obesity affects 1 billion+ people worldwide, and oral dosing can widen adoption versus injections.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThree oral programs, three distinct markets\u003c\/li\u003e\n\u003cli\u003eLarge, scalable disease targets\u003c\/li\u003e\n\u003cli\u003eProduct development drives growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eViking’s oral pipeline targets huge markets with standout upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eViking Therapeutics, Inc.'s product development is centered on VK2809 for MASH and VK2735 for obesity, both large existing markets where better oral options can win share. VK2809 showed up to 62% liver-fat reduction at 12 weeks, while obesity now affects over 1 billion people worldwide. VK0214 adds a rare-disease angle in X-linked adrenoleukodystrophy.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVK2809\u003c\/td\u003e\n\u003ctd\u003eMASH\u003c\/td\u003e\n\u003ctd\u003eNew drug for existing market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVK2735\u003c\/td\u003e\n\u003ctd\u003eObesity\u003c\/td\u003e\n\u003ctd\u003eOral expansion in huge market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVK0214\u003c\/td\u003e\n\u003ctd\u003eX-ALD\u003c\/td\u003e\n\u003ctd\u003eRare-disease product development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNASH and NAFLD liver diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVK2809 expands Viking Therapeutics, Inc. into two liver-disease segments: biopsy-confirmed NASH and NAFLD, both large parts of the metabolic-liver market. NASH affects about 1 in 20 adults globally, and NAFLD about 1 in 4, so one asset can reach a broad pool. That diversifies Viking Therapeutics, Inc. beyond a single indication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHip-fracture recovery diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVK5211 broadens Viking Therapeutics, Inc. beyond liver and diabetes into musculoskeletal recovery after non-elective hip-fracture surgery. Hip fractures drive about 300,000 U.S. hospitalizations a year, and roughly 20% to 30% of older adults die within 1 year, so the unmet need is large. That makes this a clear diversification play into a separate, high-burden recovery market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eType 2 diabetes diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVK0612’s move into type 2 diabetes is diversification into a separate metabolic market from NASH, NAFLD, and X-linked adrenoleukodystrophy. That expands Viking Therapeutics, Inc.’s disease reach beyond rare and liver-focused programs into a much larger field: 589 million adults lived with diabetes worldwide in 2024, and about 90% had type 2 diabetes. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eX-linked adrenoleukodystrophy diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVK0214 pushes Viking Therapeutics into X-linked adrenoleukodystrophy, a rare disease with an estimated incidence of about 1 in 17,000 births and no broadly approved cure. That is a new product and a new commercial field beyond its liver and diabetes pipeline, so it fits Ansoff diversification with higher risk but also a new orphan-drug revenue pool.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVK0214 targets X-linked adrenoleukodystrophy\u003c\/li\u003e\n\u003cli\u003eNew product, new rare-disease market\u003c\/li\u003e\n\u003cli\u003eBeyond Viking Therapeutics' liver and diabetes focus\u003c\/li\u003e\n\u003cli\u003eOrphan indication means smaller but higher-value pool\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFour-program spread across disease classes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eViking Therapeutics, Inc. spreads risk across four programs, not one asset. Its pipeline spans obesity and metabolic disease, thyroid hormone receptor beta, muscle-wasting disease, and a rare metabolic disorder, so the Company is not tied to a single disease or readout.\u003c\/p\u003e\n\u003cp\u003eThat breadth matters for a clinical-stage biopharmaceutical Company with no 2025 product revenue and a cash balance of about $808 million as of Q4 2025, giving it room to fund more than one path. One-line takeaway: four shots at value creation lower single-program risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFour active programs across four disease areas\u003c\/li\u003e\n\u003cli\u003eNot dependent on one drug or one market\u003c\/li\u003e\n\u003cli\u003eBroad clinical diversification for a biotech\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eViking’s 4-Front Pipeline Spreads Risk, Expands Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eViking Therapeutics, Inc. uses diversification by moving one pipeline across four distinct markets: liver disease, hip-fracture recovery, type 2 diabetes, and X-linked adrenoleukodystrophy. With no 2025 product revenue and about $808 million cash at Q4 2025, it can fund multiple shots on goal. That lowers single-asset risk while keeping upside in both large and orphan markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVK2809\u003c\/td\u003e\n\u003ctd\u003eLiver disease\u003c\/td\u003e\n\u003ctd\u003eNASH, NAFLD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVK5211\u003c\/td\u003e\n\u003ctd\u003ePost-hip-fracture recovery\u003c\/td\u003e\n\u003ctd\u003e~300,000 U.S. cases a year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVK0612\u003c\/td\u003e\n\u003ctd\u003eType 2 diabetes\u003c\/td\u003e\n\u003ctd\u003e589 million adults with diabetes in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVK0214\u003c\/td\u003e\n\u003ctd\u003eRare disease\u003c\/td\u003e\n\u003ctd\u003eX-linked adrenoleukodystrophy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235144048905,"sku":"vktx-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/vktx-ansoff-matrix.webp?v=1785735406","url":"https:\/\/dcfanalyst.com\/products\/vktx-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}